{"ok":true,"nota":{"id":"9c1120f3b0ec8ff7","slug":"un-metodo-nuevo-estima-mejor-cuanto-protege-la-vacuna-contra-el-covid--9c1120","titulo":"Un método nuevo estima mejor cuánto protege la vacuna contra el COVID cuando faltan datos clave","resumen":"Investigadores emularon un ensayo clínico con datos observacionales de un gran sistema de salud de California para estimar la efectividad del refuerzo bivalente contra COVID. Compararon dos métodos de control de sesgos ocultos en la comparación.","fuente":"medrxiv","fuenteNombre":"medRxiv · preprints","color":"#1f7a4d","autor":"Schaeffer, B., Chervo, T., Elkin, E. P., Hanage, W. P., Nugent, J. R., Rubin, I. N., Shi, J., Skarbinski, J., Boyer, C. ","url":"https://www.medrxiv.org/content/10.64898/2026.10.21.26366144v1?rss=1","imagen":"/hoy/portada/9c1120f3b0ec8ff7","tema":"ciencia","subtemas":["vacunas","covid-19","metodología epidemiológica","efectividad vacunal","estudios observacionales"],"entidades":["Kaiser Permanente","California"],"formato":"dato","entretenimiento":false,"pubTs":"2026-10-24T00:00:00.000Z","indexTs":"2026-10-24T16:44:51.482Z","hash":"ae61ec795495efbd25987088dcdc4c49cbbba670d47c11a7a05dd56d1f365820","tsa":{"time":"Oct 24 16:45:14 2026 GMT","provider":"freetsa.org","sobre":"sello"},"stats":{"views":0,"likes":0,"clicks":0,"dwell":0},"tipo":"normal","registro":"hallazgo","porQueImporta":"Cuando se evalúa una vacuna con datos de la vida real, quienes se vacunan suelen ser distintos en cuidados y hábitos, y eso puede inflar o achicar el beneficio que se ve. Este trabajo busca medir ese sesgo en vez de ignorarlo. Para quien decide si ponerse un refuerzo, la diferencia entre “protege mucho” y “protege algo” importa. Los autores reconocen que sus métodos todavía dejan un margen de error, así que el número debe leerse con cautela.","quienFirma":"Kaiser Permanente Northern California (principal institución según el material recibido)","confianza":"preprint","consulta":null},"sello":{"hash":"ae61ec795495efbd25987088dcdc4c49cbbba670d47c11a7a05dd56d1f365820","sello":"f35070091f993b5b15921f6a1d30d6c121078335bd3df40e1b6a7c542dccc7c4","beacon":{"drand":{"cadena":"8990e7a9aaed2ffed73dbd7092123d6f289930540d7651336225dc172e51b2ce","ronda":6580975,"aleatorio":"7cce22f6f8f0e18a1e57d3c0d55b5004bf079b568a9a9f143dc9251a504825bd","tiempo":"2026-10-24T16:44:30.000Z"},"nist":{"cadena":2,"pulso":1997681,"salida":"C5248B3EE24B422962809C61551C0ED22A554FF83DF586AF6189AC5F408A5DD6B8269834835CE193FDEC10C180159B7695EE635C161F0BDB8944F4CE7E0AE962","tiempo":"2026-10-24T16:44:00.000Z"},"noAntes":"2026-10-24T16:44:30.000Z"},"verificacion":{"drand":true,"nist":true},"tsa":{"time":"Oct 24 16:45:14 2026 GMT","provider":"freetsa.org","sobre":"sello"},"original":{"titulo":"Emulating a vaccine target trial under unmeasured confounding: single and double negative control methods","descripcion":"Estimating vaccine effectiveness (VE) for symptom-driven outcomes in observational settings remains challenging due to unmeasured differences in health-seeking behavior between vaccine groups. This challenge persists even with target trial emulation, which primarily addresses design-related biases. The test negative design, a popular alternative design for estimating VE, can reduce bias due to unmeasured confounding by health-seeking but often deviates from the design principles of trial emulation. Here, we emulate a target trial to estimate relative VE of COVID-19 bivalent booster in a cohort of Kaiser Permanente of Northern California members and provide evidence for residual unmeasured co","pubDate":"2026-10-24","url":"https://www.medrxiv.org/content/10.64898/2026.10.21.26366144v1?rss=1"},"indexado":"2026-10-24T16:44:51.482Z"}}